References
- United States Food and Drug Administration. Neuropsychiatric events with use of montelukast in pediatric patients. 2019 Sep 27. [accessed 2021 Mar 15]. https://www.fda.gov/media/131035/download.
- Winkel JS, Damkier P, Hallas J, Henriksen DP. Treatment with montelukast and antidepressive medication-a symmetry analysis. Pharmacoepidemiol Drug Saf. 2018;27(12):1409–1415. doi:10.1002/pds.4638.
- Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol. 2009;5(6):639–658. doi:10.1586/eci.09.
- Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf. 2018;41(3):253–265. doi:10.1007/s40264-017-0607-1.
- Scott KM, Von Korff M, Ormel J, Zhang M, Bruffaerts R, Alonso J, Kessler RC, Tachimori H, Karam E, Levinson D, et al. Mental disorders among adults with asthma: results from the World Mental Health Survey. Gen Hosp Psychiatry. 2007;29(2):123–133. doi:10.1016/j.genhosppsych.2006.12.006.
- Chen VCH, Wang TN, Liao YT, Lin TC, Stewart R, Lee CT. Asthma and self-harm: a population-based cohort study in Taiwan. J Psychosom Res. 2014;77(6):462–467. doi:10.1016/j.jpsychores.2014.08.017.
- Pratt N, Chan EW, Choi NK, Kimura M, Kimura T, Kubota K, Lai EC, Man KKC, Ooba N, Park B, et al. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol Drug Saf. 2015;24(8):858–864. doi:10.1002/pds.3780.
- Dyson TE, Cantrell MA, Lund BC. Lack of Association between 5α-Reductase Inhibitors and Depression. J Urol. 2020;204(4):793–798. doi:10.1097/JU.0000000000001079.
- Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–484.
- Zhou EH, Kaplan S, Mosholder A, Moeny D, Ding Y, Wu Y, Iyasu S, Hammad TA. Antidepressant medication dispensing among montelukast initiators. J Asthma. 2013;50(9):990–995. doi:10.3109/02770903.2013.823445.
- Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: what is the evidence? Drug Saf. 2011;34(7):533–544. doi:10.2165/11587260-000000000-00000.
- Jick H, Hagberg KW, Egger P. Rate of suicide in patients taking montelukast. Pharmacotherapy. 2009;29(2):165–166. doi:10.1592/phco.29.2.165.
- Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol. 2012;130(2):368–375. doi:10.1016/j.jaci.2012.04.035.
- Sessa M, Mascolo A, D’Agostino B, Casciotta A, D’Agostino V, Michele FD, Polverino M, Spaziano G, Andersen MP, Kragholm K, et al. Relationship between gender and the effectiveness of montelukast: An Italian/Danish Register-Based Retrospective Cohort Study. Front Pharmacol. 2018;9:844. doi:10.3389/fphar.2018.00844.
- Esposito R, Spaziano G, Giannattasio D, Ferrigno F, Liparulo A, Rossi A, Roviezzo F, Sessa M, Falciani M, Berrino L, et al. Montelukast improves symptoms and lung function in asthmatic women compared with men. Front Pharmacol. 2019;10:1094. doi:10.3389/fphar.2019.01094.
- Trivedi RB, Post EP, Sun H, Pomerantz A, Saxon AJ, Piette JD, Maynard C, Arnow B, Curtis I, Fihn SD, et al. Prevalence, comorbidity, and prognosis of mental health among US veterans. Am J Public Health. 2015;105(12):2564–2569. doi:10.2105/AJPH.2015.302836.